

# Vittorio Martinelli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5261501/publications.pdf>

Version: 2024-02-01

89  
papers

5,133  
citations

147801

31  
h-index

88630

70  
g-index

90  
all docs

90  
docs citations

90  
times ranked

4972  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. <i>Lancet, The</i> , 2001, 357, 1576-1582.	13.7	1,025
2	Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2009, 374, 1503-1511.	13.7	551
3	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1013-1024.	3.0	249
4	Cortical adaptation in patients with MS: a cross-sectional functional MRI study of disease phenotypes. <i>Lancet Neurology, The</i> , 2005, 4, 618-626.	10.2	235
5	High frequency of intestinal T <sub>H</sub> 17 cells correlates with microbiota alterations and disease activity in multiple sclerosis. <i>Science Advances</i> , 2017, 3, e1700492.	10.3	228
6	Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathies. <i>Annals of Neurology</i> , 2018, 83, 283-294.	5.3	160
7	Multimodal evoked potentials to assess the evolution of multiple sclerosis: a longitudinal study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 1030-1035.	1.9	130
8	A spinal cord MRI study of benign and secondary progressive multiple sclerosis. <i>Journal of Neurology</i> , 1996, 243, 502-505.	3.6	115
9	Anxiety and depression in multiple sclerosis patients around diagnosis. <i>Journal of the Neurological Sciences</i> , 2011, 307, 86-91.	0.6	105
10	Functional network connectivity abnormalities in multiple sclerosis: Correlations with disability and cognitive impairment. <i>Multiple Sclerosis Journal</i> , 2018, 24, 459-471.	3.0	105
11	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. <i>Neurology</i> , 2018, 90, e823-e831.	1.1	102
12	The brief international cognitive assessment for multiple sclerosis (BICAMS): normative values with gender, age and education corrections in the Italian population. <i>BMC Neurology</i> , 2014, 14, 171.	1.8	99
13	Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study. <i>Lancet Neurology, The</i> , 2018, 17, 133-142.	10.2	98
14	Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes. <i>Multiple Sclerosis Journal</i> , 2014, 20, 147-155.	3.0	94
15	Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, jnnp-2014-309690.	1.9	90
16	Paramagnetic Rim Lesions are Specific to Multiple Sclerosis: An International Multicenter 3T MRI Study. <i>Annals of Neurology</i> , 2020, 88, 1034-1042.	5.3	89
17	Leptomeningeal gadolinium enhancement across the spectrum of chronic neuroinflammatory diseases. <i>Neurology</i> , 2017, 88, 1439-1444.	1.1	85
18	Communicating the diagnosis of multiple sclerosis - a qualitative study. <i>Multiple Sclerosis Journal</i> , 2007, 13, 763-769.	3.0	77

#	ARTICLE	IF	CITATIONS
19	Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. <i>Multiple Sclerosis Journal</i> , 2016, 22, 511-519.	3.0	76
20	A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS. <i>Neurology</i> , 2009, 73, 1842-1848.	1.1	74
21	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. <i>Neurology</i> , 2018, 90, e832-e839.	1.1	74
22	Late onset multiple sclerosis: clinical characteristics, prognostic factors and differential diagnosis. <i>Neurological Sciences</i> , 2004, 25, s350-s355.	1.9	71
23	Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. <i>Neurology</i> , 2011, 77, 1887-1895.	1.1	68
24	Brain and cord imaging features in neuromyelitis optica spectrum disorders. <i>Annals of Neurology</i> , 2019, 85, 371-384.	5.3	66
25	Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1315-1326.	3.0	62
26	Prognostic value of serum neurofilaments in patients with clinically isolated syndromes. <i>Neurology</i> , 2019, 92, e733-e741.	1.1	57
27	Long-term disability progression in primary progressive multiple sclerosis: a 15-year study. <i>Brain</i> , 2017, 140, 2814-2819.	7.6	51
28	The Multiple Sclerosis Knowledge Questionnaire: a self-administered instrument for recently diagnosed patients. <i>Multiple Sclerosis Journal</i> , 2010, 16, 100-111.	3.0	50
29	Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1506-1508.	3.0	41
30	<i>MYD88</i> L265P mutation and interleukin<math>\alpha</math>10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study. <i>British Journal of Haematology</i> , 2021, 193, 497-505.	2.5	41
31	Cognitive reserve, cognition, and regional brain damage in MS: A 2&#x2013;year longitudinal study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 372-381.	3.0	40
32	A pharmacogenetic study implicates <sc><i>SLC9a9</i></sc> in multiple sclerosis disease activity. <i>Annals of Neurology</i> , 2015, 78, 115-127.	5.3	39
33	A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients. <i>BMC Neurology</i> , 2015, 15, 204.	1.8	31
34	In vivo structural and functional assessment of optic nerve damage in neuromyelitis optica spectrum disorders and multiple sclerosis. <i>Scientific Reports</i> , 2019, 9, 10371.	3.3	31
35	Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome. <i>Neurology</i> , 2022, 98, .	1.1	31
36	Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab&#x2013;treated multiple sclerosis patients. <i>Annals of Neurology</i> , 2019, 85, 606-610.	5.3	30

#	ARTICLE	IF	CITATIONS
37	Abnormalities of the executive control network in multiple sclerosis phenotypes: An fMRI effective connectivity study. <i>Human Brain Mapping</i> , 2016, 37, 2293-2304.	3.6	29
38	Smart watch, smarter EDSS: Improving disability assessment in multiple sclerosis clinical practice. <i>Journal of the Neurological Sciences</i> , 2017, 383, 166-168.	0.6	29
39	Diagnosing autoimmune encephalitis in a real-world single-centre setting. <i>Journal of Neurology</i> , 2020, 267, 449-460.	3.6	28
40	Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients. <i>European Journal of Neurology</i> , 2013, 20, 1060-1067.	3.3	27
41	Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1490-1499.	3.0	26
42	Working memory network dysfunction in relapse-onset multiple sclerosis phenotypes: A clinical-imaging evaluation. <i>Multiple Sclerosis Journal</i> , 2017, 23, 577-587.	3.0	26
43	Clinical significance of the number of oligoclonal bands in patients with clinically isolated syndromes. <i>Journal of Neuroimmunology</i> , 2015, 289, 62-67.	2.3	20
44	Progressive visual function impairment as the predominant symptom of the transition phase to secondary progressive multiple sclerosis: A case report. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 24, 69-71.	2.0	20
45	Dysregulated copper transport in multiple sclerosis may cause demyelination via astrocytes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	19
46	Free Light Chains and Intrathecal B Cells Activity in Multiple Sclerosis: A Prospective Study and Meta-Analysis. <i>Multiple Sclerosis International</i> , 2016, 2016, 1-9.	0.8	18
47	Multiple biomarkers improve the prediction of multiple sclerosis in clinically isolated syndromes. <i>Acta Neurologica Scandinavica</i> , 2017, 136, 454-461.	2.1	18
48	Acquired haemophilia A as a secondary autoimmune disease after alemtuzumab treatment in multiple sclerosis: A case report. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 403-405.	2.0	18
49	Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis. <i>Clinical Therapeutics</i> , 2019, 41, 249-260.e18.	2.5	17
50	The CSF p-tau181/A $\beta$ 242 Ratio Offers a Good Accuracy <i>in Vivo</i> in the Differential Diagnosis of Alzheimer's Dementia. <i>Current Alzheimer Research</i> , 2019, 16, 587-595.	1.4	17
51	Validation of 1-year predictive score of long-term response to interferon- $\beta$ in everyday clinical practice multiple sclerosis patients. <i>European Journal of Neurology</i> , 2015, 22, 973-980.	3.3	16
52	Refractory anti-NMDAR encephalitis successfully treated with bortezomib and associated movements disorders controlled with tramadol: a case report with literature review. <i>Journal of Neurology</i> , 2020, 267, 2462-2468.	3.6	15
53	Use of herbal remedies by multiple sclerosis patients: a nation-wide survey in Italy. <i>Neurological Sciences</i> , 2016, 37, 613-622.	1.9	14
54	DT MRI microstructural cortical lesion damage does not explain cognitive impairment in MS. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1918-1928.	3.0	13

#	ARTICLE	IF	CITATIONS
55	Caesarean section and infant formula feeding are associated with an earlier age of onset of multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 33, 75-77.	2.0	13
56	Spinal Cord Atrophy in Neuromyelitis Optica Spectrum Disorders Is Spatially Related to Cord Lesions and Disability. <i>Radiology</i> , 2020, 297, 154-163.	7.3	13
57	Effectiveness and baseline factors associated to fingolimod response in a real-world study on multiple sclerosis patients. <i>Journal of Neurology</i> , 2018, 265, 896-905.	3.6	12
58	Combination therapy. <i>Neurological Sciences</i> , 2006, 27, s350-s354.	1.9	11
59	Predictors of effectiveness of multidisciplinary rehabilitation treatment on motor dysfunction in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 862-870.	3.0	11
60	Disease-modifying treatments modulate myeloid cells in multiple sclerosis patients. <i>Neurological Sciences</i> , 2018, 39, 373-376.	1.9	11
61	Treatment Challenges of a Primary Vertebral Artery Aneurysm Causing Recurrent Ischemic Strokes. <i>Case Reports in Neurological Medicine</i> , 2017, 2017, 1-3.	0.4	9
62	CSF extracellular vesicles and risk of disease activity after a first demyelinating event. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1606-1610.	3.0	9
63	Disclosing the diagnosis of multiple sclerosis: The Profile Project. <i>Journal of Neurology</i> , 2012, 259, 2605-2610.	3.6	8
64	Clinical deterioration due to co-occurrence of multiple sclerosis and glioblastoma: report of two cases. <i>Neurological Sciences</i> , 2017, 38, 361-364.	1.9	8
65	Induction versus escalation therapy. <i>Neurological Sciences</i> , 2005, 26, s193-s199.	1.9	7
66	The Communication of Multiple Sclerosis Diagnosis: The Patients'™ Perspective. <i>Multiple Sclerosis International</i> , 2015, 2015, 1-7.	0.8	7
67	Cortico-subcortical functional connectivity modifications in fatigued multiple sclerosis patients treated with fampridine and amantadine. <i>European Journal of Neurology</i> , 2021, 28, 2249-2258.	3.3	7
68	Digital epidemiology confirms a latitude gradient of MS in France. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 129-131.	2.0	6
69	Sturge-Weber syndrome with an unusual onset in the sixth decade: a case report. <i>Neurological Sciences</i> , 2012, 33, 949-950.	1.9	5
70	Mapping face encoding using functional MRI in multiple sclerosis across disease phenotypes. <i>Brain Imaging and Behavior</i> , 2017, 11, 1238-1247.	2.1	5
71	EEG correlates of cognitive impairment in MS. <i>Italian Journal of Neurological Sciences</i> , 1998, 19, S413-S417.	0.1	4
72	Opinion & Special Articles: Professionalism in neurology. <i>Neurology</i> , 2014, 83, e12-5.	1.1	4

#	ARTICLE	IF	CITATIONS
73	Primary progressive multiple sclerosis presenting with severe predominant cognitive impairment and psychiatric symptoms: A challenging case. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1558-1561.	3.0	4
74	Neuromyelitis optica spectrum disorder and multiple sclerosis in a Sardinian family. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 73-76.	2.0	4
75	Assessing the role of innovative therapeutic paradigm on multiple sclerosis treatment response. <i>Acta Neurologica Scandinavica</i> , 2018, 138, 447-453.	2.1	4
76	Reply to "Serum Neurofilaments as Candidate Biomarkers of Natalizumab Progressive Multifocal Leukoencephalopathy". <i>Annals of Neurology</i> , 2019, 86, 324-324.	5.3	4
77	Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) after SARS-CoV-2 pneumonia. <i>Neurological Sciences</i> , 2021, 42, 4373-4375.	1.9	4
78	Assessing seasonal dynamics of Guillain-Barré syndrome with search engine query data. <i>Neurological Sciences</i> , 2019, 40, 1015-1018.	1.9	3
79	Stress related to COVID-19 pandemic as a trigger for disease activity in multiple sclerosis: a case report. <i>Neurological Sciences</i> , 2021, 42, 3969-3971.	1.9	3
80	Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab. <i>Viruses</i> , 2016, 8, 128.	3.3	2
81	Progressive ataxia in a natalizumab-treated multiple sclerosis patient: the dark side of JC virus infection. <i>European Journal of Neurology</i> , 2016, 23, e39-40.	3.3	2
82	Dynamic pattern of clinical and MRI findings in a tumefactive demyelinating lesion: A case report. <i>Journal of the Neurological Sciences</i> , 2016, 361, 184-186.	0.6	2
83	Moyamoya disease mimicking the first attack of multiple sclerosis. <i>Journal of Neurology</i> , 2017, 264, 1005-1007.	3.6	2
84	Necrotic-hemorrhagic myelitis: A rare malignant variant of parainfectious acute disseminated encephalomyelitis in childhood. <i>Journal of the Neurological Sciences</i> , 2018, 384, 58-60.	0.6	2
85	Severe disease activity in a patient with multiple sclerosis after daclizumab discontinuation. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 57-59.	2.0	1
86	Risk attitude and personality in people with multiple sclerosis facing the choice of different disease-modifying therapy scenarios. <i>Journal of the Neurological Sciences</i> , 2020, 417, 117064.	0.6	1
87	Gut-oriented interventions in patients with multiple sclerosis: fact or fiction?. <i>European Review for Medical and Pharmacological Sciences</i> , 2022, 26, 935-946.	0.7	1
88	MR T2-relaxation time as an indirect measure of brain water content and disease activity in NMOSD. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, , jnnp-2022-328956.	1.9	1
89	Thrombolysis with rt-PA for an ischemic stroke in boy treated with Fontan operation. <i>Journal of Pediatric Neurology</i> , 2015, 09, 497-500.	0.2	0